Table II.
Clinical presentation and outcomes of all individuals in the Cleveland Clinic COVID-19 Research Registry with a positive SARS-CoV-2 test stratified by intranasal corticosteroid use
| Variables | No intranasal corticosteroids | Intranasal corticosteroids | P∗ |
|---|---|---|---|
| n | 61,960 | 10,187 | |
| Clinical presentation | |||
| Cough | 28,237 (45.6) | 5557 (54.5) | <.001 |
| Fever | 15,829 (25.5) | 3349 (32.9) | <.001 |
| Fatigue | 20,938 (33.8) | 4067 (39.9) | <.001 |
| Sputum production | 3332 (5.4) | 863 (8.5) | <.001 |
| Flu-like symptoms | 17,526 (28.3) | 4061 (39.9) | <.001 |
| Dyspnea | 14,817 (23.9) | 3090 (30.3) | <.001 |
| Diarrhea | 4392 (7.1) | 1007 (9.9) | <.001 |
| Loss of appetite | 4339 (7.0) | 854 (8.4) | <.001 |
| Vomiting | 7518 (12.1) | 1490 (14.6) | <.001 |
| Outcomes | |||
| Hospitalization | 10,932 (17.6) | 1676 (16.5) | .003 |
| Admission to the intensive care unit | 2559 (4.1) | 376 (3.7) | .04 |
| Hospital mortality | 1649 (2.7) | 231 (2.3) | .023 |
COVID-19, coronavirus disease 2019; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
Data are presented as n (%).
∗
Unadjusted analysis comparing intranasal corticosteroid users to nonusers.